Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer

Model scores of the 29,894 trials active now.

Model score 28% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patients mustheartchemotherapyradiationstable
  Phrases that lowered it: patients whosolidtrialtumorscriteria patients
• Sponsor's past termination rate: 16.3% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 20.9% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 26 (lowers risk) · Sponsor's track record
• Minimum age: 19 (lowers risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 6934 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 49 (raises risk) · Sponsor's track record
• Responsible party: sponsor (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma NCT01014351 · started 2010 · scored riskier than 95% of active trials completed
• Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy NCT00949949 · started 2009 · scored riskier than 41% of active trials completed
• A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma NCT01797523 · started 2013 · scored riskier than 83% of active trials completed
• Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck NCT01133678 · started 2010 · scored riskier than 96% of active trials terminated
• Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate NCT01582009 · started 2010 · scored riskier than 95% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.